Published in Clin Vaccine Immunol on February 20, 2008
A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol (2010) 0.99
Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother (2013) 0.94
Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol (2008) 0.89
Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice. PLoS One (2010) 0.83
Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins. Clin Vaccine Immunol (2012) 0.81
Sang Froid in a time of trouble: is a vaccine against HIV possible? J Int AIDS Soc (2009) 0.81
Polymeric Materials for Gene Delivery and DNA Vaccination. Adv Mater (2008) 0.76
Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression. J Virol (2016) 0.75
The Immune Response in Measles: Virus Control, Clearance and Protective Immunity. Viruses (2016) 0.75
Measles antibody: reevaluation of protective titers. J Infect Dis (1990) 3.77
Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol (2001) 3.27
Neonatal and early life vaccinology. Vaccine (2001) 3.25
FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol (2007) 3.04
Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr (1977) 2.66
Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet (1991) 2.42
Immunization without needles. Nat Rev Immunol (2005) 2.02
Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol (1996) 2.01
Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods (1981) 1.96
Genetic variability of the glycoprotein genes of current wild-type measles isolates. Virology (1992) 1.89
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA (1998) 1.83
DNA and RNA-based vaccines: principles, progress and prospects. Vaccine (1999) 1.76
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
The 1st International Standard for anti-measles serum. Biologicals (1991) 1.67
MEASLES IMMUNIZATION WITH KILLED VIRUS VACCINE. SERUM ANTIBODY TITERS AND EXPERIENCE WITH EXPOSURE TO MEASLES EPIDEMIC. Am J Dis Child (1965) 1.66
Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A (2000) 1.63
Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis (1999) 1.62
DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol (1998) 1.57
Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol (2000) 1.52
Progress in reducing measles mortality--worldwide, 1999-2003. MMWR Morb Mortal Wkly Rep (2005) 1.47
A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med (2003) 1.39
Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol (2000) 1.39
Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. J Infect Dis (1992) 1.38
Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J Virol (1990) 1.36
Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med (1999) 1.35
Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis (1997) 1.29
IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol (1999) 1.28
DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc Natl Acad Sci U S A (1997) 1.27
Differential mortality by measles vaccine titer and sex. J Infect Dis (1993) 1.20
A plasmid-based self-amplifying Sindbis virus vector. Hum Gene Ther (1995) 1.19
Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A (2005) 1.16
Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol (2003) 1.15
Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine (2001) 1.14
Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis (2002) 1.14
Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol (2001) 1.13
Child mortality following standard, medium or high titre measles immunization in West Africa. Int J Epidemiol (1996) 1.12
Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol (2005) 1.05
Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice. J Gen Virol (1988) 1.04
Recombinant bacille Calmette-Guérin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia. J Infect Dis (1997) 1.04
Monkeys in measles research. Curr Top Microbiol Immunol (1995) 1.02
Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol (2005) 1.00
Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology (2000) 0.99
Loss of maternal measles antibody during infancy in an African city. Int J Epidemiol (1989) 0.98
Measles active and passive immunity in a worldwide perspective. Prog Med Virol (1989) 0.98
Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J Immunol (2006) 0.98
Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. J Infect Dis (2004) 0.98
Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther (2000) 0.97
Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun (2003) 0.95
Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis (2004) 0.94
Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. J Infect Dis (2007) 0.93
Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol (2003) 0.90
Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine (2004) 0.87
Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine (2004) 0.84
Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge. J Infect Dis (2003) 0.83
Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates. Vaccine (2002) 0.83
Priming of measles virus-specific humoral- and cellular-immune responses in macaques by DNA vaccination. Vaccine (2002) 0.83
Alphavirus cDNA-based expression vectors: effects of RNA transcription and nuclear export. Biotechnol Bioeng (2003) 0.82
Loss of maternally-acquired measles antibody during infancy in Ilorin, Nigeria. J Trop Pediatr (1995) 0.78
Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus. Virology (2006) 0.77
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2010) 9.18
Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2010) 6.93
Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med (2009) 4.70
Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke (2003) 4.13
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke (2008) 4.06
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79
Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Stroke (2005) 3.74
Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med (2005) 3.38
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med (2008) 3.17
Analysis of changing paradigms of management in 179 patients with spinal tuberculosis over a 12-year period and proposal of a new management algorithm. World Neurosurg (2013) 2.94
Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med (2010) 2.59
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection. J Virol (2002) 2.55
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine (2011) 2.53
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A (2009) 2.42
Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Circulation (2005) 2.38
Measles. Lancet (2011) 2.37
Prevalence of asthma and asthma action plans in South Australia: population surveys from 1990 to 2001. Med J Aust (2003) 2.23
Global measles elimination. Nat Rev Microbiol (2006) 2.21
Trends in hospital admissions and mortality from asthma and chronic obstructive pulmonary disease in Australia, 1993-2003. Med J Aust (2007) 2.20
Remote evaluation of acute ischemic stroke: reliability of National Institutes of Health Stroke Scale via telestroke. Stroke (2003) 2.17
The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome. Nat Biotechnol (2012) 2.14
A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol (2009) 2.10
Adverse drug events and medication errors in Australia. Int J Qual Health Care (2003) 2.03
MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr Blood Cancer (2008) 2.01
How valid are self-reported height and weight? A comparison between CATI self-report and clinic measurements using a large cohort study. Aust N Z J Public Health (2006) 1.97
Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care (2013) 1.93
The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med (2002) 1.92
The North West Adelaide Health Study: detailed methods and baseline segmentation of a cohort for selected chronic diseases. Epidemiol Perspect Innov (2006) 1.91
The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis (2002) 1.90
The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis (2007) 1.89
Declining stroke rates in Californian children with sickle cell disease. Blood (2004) 1.83
Luciferase imaging of a neurotropic viral infection in intact animals. J Virol (2003) 1.83
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood (2009) 1.83
Sickle cell disease: the neurological complications. Ann Neurol (2002) 1.77
Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer (2010) 1.75
Clinical outcome of hemoperfusion in poisoned patients. Blood Purif (2010) 1.72
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol (2008) 1.71
Diastolic dysfunction is associated with myocardial viral load in simian immunodeficiency virus-infected macaques. AIDS (2012) 1.68
Serum total antioxidant statuses of survivors and nonsurvivors after acute paraquat poisoning. Clin Toxicol (Phila) (2009) 1.67
Simultaneous quantitative analysis of sphingoid base 1-phosphates in biological samples by o-phthalaldehyde precolumn derivatization after dephosphorylation with alkaline phosphatase. Anal Biochem (2002) 1.60
Platelet activation and platelet-monocyte aggregate formation contribute to decreased platelet count during acute simian immunodeficiency virus infection in pig-tailed macaques. J Infect Dis (2013) 1.57
Organized stroke care. Stroke (2006) 1.56
BAK alters neuronal excitability and can switch from anti- to pro-death function during postnatal development. Dev Cell (2003) 1.56
The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: from mechanism to treatment. J Neurovirol (2008) 1.54
Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology (2008) 1.54
Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. Am J Respir Crit Care Med (2008) 1.53
Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood (2013) 1.52
Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy. J Infect Dis (2004) 1.51
Wounding: the primary mode of Seoul virus transmission among male Norway rats. Am J Trop Med Hyg (2004) 1.50
Coordinated regulation of SIV replication and immune responses in the CNS. PLoS One (2009) 1.49
Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol (2007) 1.47
Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood (2006) 1.45
Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. Nat Biotechnol (2013) 1.45
Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med (2013) 1.45
The sulfurtransferase activity of Uba4 presents a link between ubiquitin-like protein conjugation and activation of sulfur carrier proteins. Biochemistry (2008) 1.44
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A (2011) 1.44
The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials (2009) 1.43
Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. J Neurosci (2011) 1.43
Comparative analysis of diagnostic accuracy of different brain biopsy procedures. Neurol India (2006) 1.43
Association between plasma paraquat level and outcome of paraquat poisoning in 375 paraquat poisoning patients. Clin Toxicol (Phila) (2008) 1.42
Pathophysiology and treatment of stroke in sickle-cell disease: present and future. Lancet Neurol (2006) 1.39
A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med (2003) 1.39
Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis (2007) 1.38
REACH: clinical feasibility of a rural telestroke network. Stroke (2005) 1.38
Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis (2010) 1.37
Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J (2009) 1.36
Comparison between kidney and hemoperfusion for paraquat elimination. J Korean Med Sci (2009) 1.35
A mechanistic role for type III IFN-λ1 in asthma exacerbations mediated by human rhinoviruses. Am J Respir Crit Care Med (2011) 1.31
Suppression of human immunodeficiency virus replication during acute measles. J Infect Dis (2002) 1.31
Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke (2006) 1.31
Prevalence of hypertension by duration and age at exposure to the stroke belt. J Am Soc Hypertens (2010) 1.29
Regulatory T cells enhance persistence of the zoonotic pathogen Seoul virus in its reservoir host. Proc Natl Acad Sci U S A (2007) 1.28
Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy. Clin Infect Dis (2008) 1.27
Class II fusion protein of alphaviruses drives membrane fusion through the same pathway as class I proteins. J Cell Biol (2005) 1.25
Gamma interferon-dependent, noncytolytic clearance of sindbis virus infection from neurons in vitro. J Virol (2005) 1.25
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine (2007) 1.24
The clinical features of acute kidney injury in patients with acute paraquat intoxication. Nephrol Dial Transplant (2008) 1.24
Effect of haemoperfusion on plasma paraquat concentration in vitro and in vivo. Toxicol Ind Health (2003) 1.22
Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis (2007) 1.22
Recent advances in vaccine adjuvants. Pharm Res (2002) 1.22
Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). J Pediatr Hematol Oncol (2002) 1.22
Application of beta regression to analyze ischemic stroke volume in NINDS rt-PA clinical trials. Neuroepidemiology (2011) 1.21
Synergistic roles of antibody and interferon in noncytolytic clearance of Sindbis virus from different regions of the central nervous system. J Virol (2007) 1.21
Do people with risky behaviours participate in biomedical cohort studies? BMC Public Health (2006) 1.20
Searching for clues: tracking the pathogenesis of human immunodeficiency virus central nervous system disease by use of an accelerated, consistent simian immunodeficiency virus macaque model. J Infect Dis (2002) 1.18
Measles: immune suppression and immune responses. Int J Biochem Cell Biol (2004) 1.18
Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children. J Infect Dis (2002) 1.18
Telestroke: extending stroke expertise into underserved areas. Lancet Neurol (2006) 1.17
HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis (2009) 1.17
Teleneurology applications: Report of the Telemedicine Work Group of the American Academy of Neurology. Neurology (2013) 1.17